TXG · 10x Genomics, Inc. · Earnings Call Transcripts & Audio
$89.17
-1.19 (-1.32%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$11.17B
Shares
130.29M
Volume · Sep 30
3.75M
Avg daily vol (3M)
3.03M
10x Genomics, Inc. Earnings Call Transcripts
Quarterly earnings calls for 10x Genomics, Inc. (TXG), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲4.6%
$131.07M
−$41.91M
'22 Q3
22-11-02
▲8.8%
$156.23M
−$17.21M
'22 Q4
23-02-15
▲17.3%
$134.28M
−$50.75M
'23 Q1
23-05-03
▲28.1%
$146.82M
−$62.41M
'23 Q2
23-08-03
▲17.2%
$153.64M
−$92.99M
'23 Q3
23-11-02
▲17.8%
$183.98M
−$48.95M
'23 Q4
24-02-15
▲5%
$141.01M
−$59.95M
'24 Q1
24-04-30
▲4.3%
$153.10M
−$37.90M
'24 Q2
24-08-08
▼1.3%
$151.65M
−$35.75M
'24 Q3
24-10-29
▼10.3%
$165.02M
−$49.03M
'24 Q4
25-02-12
▲9.8%
$154.88M
−$34.36M
'25 Q1
25-05-08
▲12.9%
$172.91M
$34.54M
'25 Q2
25-08-07
▼1.7%
$149.00M
−$27.47M
'25 Q3
25-11-06
▲0.6%
$166.03M
−$16.25M
'25 Q4
26-02-12
▼2.6%
$150.84M
−$13.47M
'26 Q1
26-05-07
LATEST
▼12.6%
$151.04M
−$17.93M
'26 Q2
26-08-06
Earnings call
FY26 · Q2
2026-08-06
10x Genomics, Inc. (TXG) Q2 2026 Earnings Call Transcript
Confident tone
Atera launch and customer demand
Xenium and Visium spatial momentum
Q3-to-Q4 sequential step-up and guidance
Revenue
$151.04M
▼ 12.6% YoY Diluted EPS
$-0.14
▼ 150% YoY Gross margin
74.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
10x Genomics, Inc. (TXG) Q1 2026 Earnings Call Transcript
Confident tone
Atara launch
Single cell / FLEX growth
Spatial / Xenium momentum
Revenue
$150.84M
▼ 2.6% YoY Diluted EPS
$-0.10
Gross margin
70.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-12
10x Genomics, Inc. (TXG) Q4 2025 Earnings Call Transcript
Positive tone
Spatial / Xenium momentum
Revenue and demand environment
Single cell consumables and FLEX APEX
Revenue
$166.03M*
▲ 0.6% YoY Gross margin
68.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
10x Genomics, Inc. (TXG) Q3 2025 Earnings Call Transcript
Positive tone
Single-cell / Chromium strategy
Xenium and spatial growth
Macro and funding environment
Revenue
$149.00M
▼ 1.7% YoY Diluted EPS
$-0.22
Gross margin
67.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
10x Genomics, Inc. (TXG) Q2 2025 Earnings Call Transcript
Balanced tone
Bruker Litigation Settlement
Spatial / Xenium Growth
Chromium Consumables & Single-Cell
Revenue
$172.91M
▲ 12.9% YoY Diluted EPS
$0.28
Gross margin
72.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Annual General Meeting
Investor event
2025-06-03
10x Genomics, Inc. (TXG) June 2025 Annual General Meeting Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q1
2025-05-08
10x Genomics, Inc. (TXG) Q1 2025 Earnings Call Transcript
Cautious tone
Single Cell and Spatial Adoption
Macro/NIH Funding Environment
Workforce Reduction and Cost Actions
Revenue
$154.88M
▲ 9.8% YoY Diluted EPS
$-0.28
Gross margin
68.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-12
10x Genomics, Inc. (TXG) Q4 2024 Earnings Call Transcript
Positive tone
2025 guidance and outlook
2024 financial results
Spatial business growth
Revenue
$165.02M*
▼ 10.3% YoY Gross margin
67.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-29
10x Genomics, Inc. (TXG) Q3 2024 Earnings Call Transcript
Cautious tone
Revenue shortfall and guidance
Chromium pricing and accessibility
Commercial restructuring disruption
Revenue
$151.65M
▼ 1.3% YoY Diluted EPS
$-0.30
Gross margin
70.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
10x Genomics, Inc. (TXG) Q2 2024 Earnings Call Transcript
Cautious tone
Visium and CytAssist strength
Xenium platform and instrument sales
Single cell / Chromium momentum
Revenue
$153.10M
▲ 4.3% YoY Diluted EPS
$-0.32
Gross margin
68.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-30
10x Genomics, Inc. (TXG) Q1 2024 Earnings Call Transcript
Positive tone
Chromium transition headwinds
Platform investment balance
Spatial biology momentum
Revenue
$141.01M
▲ 5% YoY Diluted EPS
$-0.50
Gross margin
65.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-15
10x Genomics, Inc. (TXG) Q4 2023 Earnings Call Transcript
Positive tone
Xenium platform launch and adoption
GEM-X Chromium overhaul
Visium HD upcoming launch
Revenue
$183.98M*
▲ 17.8% YoY Gross margin
62.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
10x Genomics, Inc. (TXG) Q3 2023 Earnings Call Transcript
Revenue
$153.64M
▲ 17.2% YoY Diluted EPS
$-0.79
Gross margin
62.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
10x Genomics, Inc. (TXG) Q2 2023 Earnings Call Transcript
Revenue
$146.82M
▲ 28.1% YoY Diluted EPS
$-0.53
Gross margin
67.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
10x Genomics, Inc. (TXG) Q1 2023 Earnings Call Transcript
Revenue
$134.28M
▲ 17.3% YoY Diluted EPS
$-0.44
Gross margin
73.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-15
10x Genomics, Inc. (TXG) Q4 2022 Earnings Call Transcript
Revenue
$156.23M*
▲ 8.8% YoY Gross margin
76.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-02
10x Genomics, Inc. (TXG) Q3 2022 Earnings Call Transcript
Revenue
$131.07M
▲ 4.6% YoY Diluted EPS
$-0.37
Gross margin
76.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
10x Genomics, Inc. (TXG) Q2 2022 Earnings Call Transcript
Revenue
$114.61M
▼ 1.1% YoY Diluted EPS
$-0.57
Gross margin
75.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
10x Genomics, Inc. (TXG) Q1 2022 Earnings Call Transcript
Revenue
$114.50M
▲ 8.2% YoY Diluted EPS
$-0.38
Gross margin
77.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-16
10x Genomics, Inc. (TXG) Q4 2021 Earnings Call Transcript
Revenue
$143.53M*
▲ 27.9% YoY Gross margin
80.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-02
10x Genomics, Inc. (TXG) Q3 2021 Earnings Call Transcript
Revenue
$125.30M
▲ 74.5% YoY Diluted EPS
$-0.15
Gross margin
80.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
10x Genomics, Inc. (TXG) Q2 2021 Earnings Call Transcript
Revenue
$115.84M
▲ 170% YoY Diluted EPS
$-0.10
Gross margin
95.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
10x Genomics, Inc. (TXG) Q1 2021 Earnings Call Transcript
Revenue
$105.82M
▲ 47.2% YoY Diluted EPS
$-0.11
Gross margin
83.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-17
10x Genomics, Inc. (TXG) Q4 2020 Earnings Call Transcript
Revenue
$112.22M*
▲ 49% YoY Gross margin
83.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-10
10x Genomics, Inc. (TXG) Q3 2020 Earnings Call Transcript
Revenue
$71.82M
▲ 17.3% YoY Diluted EPS
$-0.65
Gross margin
79.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-11
10x Genomics, Inc. (TXG) Q2 2020 Earnings Call Transcript
Revenue
$42.91M
▼ 23.1% YoY Diluted EPS
$-0.41
Gross margin
76.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
10x Genomics, Inc. (TXG) Q1 2020 Earnings Call Transcript
Revenue
$71.91M
▲ 34.2% YoY Diluted EPS
$-0.22
Gross margin
79.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-18
10x Genomics, Inc. (TXG) Q4 2019 Earnings Call
Revenue
$75.29M
▲ 48.9% YoY Gross margin
78.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 earnings calls
Key facts
CIK
1770787
CUSIP
88025U109
13F (30d)
12 filings
10 filers
Visit website
Investor relations